PURPOSE: The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. METHODS: Patients receiving weekly paclitaxel (70 to 90 mg/m(2)) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. RESULTS: P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. CONCLUSION: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.
PURPOSE: The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. METHODS:Patients receiving weekly paclitaxel (70 to 90 mg/m(2)) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. RESULTS:P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. CONCLUSION: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.
Authors: Juan Miguel Jimenez-Andrade; Christopher M Peters; Nicole A Mejia; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh Journal: Neurosci Lett Date: 2006-07-18 Impact factor: 3.046
Authors: Christopher M Peters; Juan Miguel Jimenez-Andrade; Beth M Jonas; Molly A Sevcik; Nathan J Koewler; Joseph R Ghilardi; Gilbert Y Wong; Patrick W Mantyh Journal: Exp Neurol Date: 2006-09-26 Impact factor: 5.330
Authors: Jeff A Sloan; Lawrence Berk; Joseph Roscoe; Michael J Fisch; Edward G Shaw; Gwen Wyatt; Gary R Morrow; Amylou C Dueck Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: Stacy L Moulder; Frankie A Holmes; Anthony W Tolcher; Peter Thall; Kristine Broglio; Vicente Valero; Aman U Buzdar; Susan G Arbuck; Andrew Seidman; Gabriel N Hortobagyi Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Julie A Garrison; Jeannine S McCune; Robert B Livingston; Hannah M Linden; Julie R Gralow; Georgiana K Ellis; Howard L West Journal: Oncology (Williston Park) Date: 2003-02 Impact factor: 2.990
Authors: Nicholas Chiu; Liying Zhang; Daniela Gallo-Hershberg; Rebecca Dent; Leonard Chiu; Mark Pasetka; Jenna van Draanen; Ronald Chow; Henry Lam; Sunil Verma; Jordan Stinson; Erica Stacey; Edward Chow; Carlo DeAngelis Journal: Support Care Cancer Date: 2016-02-11 Impact factor: 3.603
Authors: Neil Majithia; Sarah M Temkin; Kathryn J Ruddy; Andreas S Beutler; Dawn L Hershman; Charles L Loprinzi Journal: Support Care Cancer Date: 2015-12-19 Impact factor: 3.603
Authors: Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto Journal: Br J Pharmacol Date: 2020-06-03 Impact factor: 8.739
Authors: Jennifer Le-Rademacher; Rahul Kanwar; Drew Seisler; Deirdre R Pachman; Rui Qin; Alexej Abyzov; Kathryn J Ruddy; Michaela S Banck; Ellen M Lavoie Smith; Susan G Dorsey; Neil K Aaronson; Jeff Sloan; Charles L Loprinzi; Andreas S Beutler Journal: Support Care Cancer Date: 2017-06-20 Impact factor: 3.603
Authors: Shivani S Shinde; Drew Seisler; Gamini Soori; Pamela J Atherton; Deirdre R Pachman; Jacqueline Lafky; Kathryn J Ruddy; Charles L Loprinzi Journal: Support Care Cancer Date: 2015-07-09 Impact factor: 3.603
Authors: Ricardo Fernandes; Sasha Mazzarello; Habeeb Majeed; Stephanie Smith; Risa Shorr; Brian Hutton; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2015-09-19 Impact factor: 3.603
Authors: Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544